Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James J Dowling

Showing results (1-10 of 174) with videos related to

Pageof 18
Sort By:
Gene Therapy|February 23, 2022
CRISPR editing as a therapeutic strategy for Duchenne muscular dystrophy-anti-Cas9 immune response casts its shadow over safety and efficacyJames J Dowling
Nature Reviews. Neurology|November 19, 2016
Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the lineJames J Dowling
Neurology|August 27, 2013
Titin and centronuclear myopathy: The tip of the iceberg for TTN-ic mutations?James J Dowling
Frontiers in Molecular Neuroscience|August 4, 2020
Zebrafish Models of <i>LAMA2</i>-Related Congenital Muscular Dystrophy (MDC1A)Lacramioara Fabian, James J Dowling
Science (New York, N.Y.)|October 24, 2024
A pro-oxidant suppresses unrelated diseasesEmanuela Pannia, James J Dowling
Neuromuscular Disorders : NMD|November 5, 2021
X-linked myotubular myopathyMichael W Lawlor, James J Dowling
Journal of Biomechanical Engineering|September 13, 2003
Analysis of body segment parameter differences between four human populations and the estimation errors of four popular mathematical modelsJennifer L Durkin, James J Dowling
Annals of Biomedical Engineering|July 19, 2006
Body segment parameter estimation of the human lower leg using an elliptical model with validation from DEXAJennifer L Durkin, James J Dowling
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 15, 2018
Dynamin 2 (DNM2) as Cause of, and Modifier for, Human Neuromuscular DiseaseMo Zhao, Nika Maani, James J Dowling
Current Opinion in Neurology|July 16, 2021
Genetic therapy for congenital myopathiesNika Maani, Sophie Karolczak, James J Dowling
Pageof 18

Showing results (1-10 of 174) with videos related to

Sort By:
Pageof 18
Gene Therapy|February 23, 2022
CRISPR editing as a therapeutic strategy for Duchenne muscular dystrophy-anti-Cas9 immune response casts its shadow over safety and efficacyJames J Dowling
Nature Reviews. Neurology|November 19, 2016
Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the lineJames J Dowling
Neurology|August 27, 2013
Titin and centronuclear myopathy: The tip of the iceberg for TTN-ic mutations?James J Dowling
Frontiers in Molecular Neuroscience|August 4, 2020
Zebrafish Models of <i>LAMA2</i>-Related Congenital Muscular Dystrophy (MDC1A)Lacramioara Fabian, James J Dowling
Science (New York, N.Y.)|October 24, 2024
A pro-oxidant suppresses unrelated diseasesEmanuela Pannia, James J Dowling
Neuromuscular Disorders : NMD|November 5, 2021
X-linked myotubular myopathyMichael W Lawlor, James J Dowling
Journal of Biomechanical Engineering|September 13, 2003
Analysis of body segment parameter differences between four human populations and the estimation errors of four popular mathematical modelsJennifer L Durkin, James J Dowling
Annals of Biomedical Engineering|July 19, 2006
Body segment parameter estimation of the human lower leg using an elliptical model with validation from DEXAJennifer L Durkin, James J Dowling
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 15, 2018
Dynamin 2 (DNM2) as Cause of, and Modifier for, Human Neuromuscular DiseaseMo Zhao, Nika Maani, James J Dowling
Current Opinion in Neurology|July 16, 2021
Genetic therapy for congenital myopathiesNika Maani, Sophie Karolczak, James J Dowling
Pageof 18